Dementia alzheimer's type and Raynaud's phenomenon

Summary:

Raynaud's phenomenon is found among people with Dementia alzheimer's type, especially for people who are male, 60+ old.

The study analyzes which people have Raynaud's phenomenon with Dementia alzheimer's type. It is created by eHealthMe based on reports of 6 people who have Dementia alzheimer's type from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On May, 22, 2022

6 people who have Dementia Alzheimer'S Type and Raynaud'S Phenomenon are studied.


What is Dementia alzheimer's type?

Dementia alzheimer's type (loss of mental ability with alzheimer's symptom) is found to be associated with 1,123 drugs and 647 conditions by eHealthMe.

What is Raynaud's phenomenon?

Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas) is found to be associated with 1,271 drugs and 818 conditions by eHealthMe.

Number of Raynaud's phenomenon in Dementia alzheimer's type reports submitted per year:

Would you have Raynaud's phenomenon when you have Dementia alzheimer's type?

Gender of people who have Dementia Alzheimer'S Type and experienced Raynaud'S Phenomenon *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Dementia Alzheimer'S Type and experienced Raynaud'S Phenomenon *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common co-existing conditions for these people *:

  1. Fungal Infection: 5 people, 83.33%
  2. Fungal Nail Infection: 1 person, 16.67%

Common drugs taken by these people *:

  1. Risperidone: 6 people, 100.00%
  2. Ramipril: 6 people, 100.00%
  3. Galantamine Hydrobromide: 4 people, 66.67%

Common symptoms for these people *:

  1. Skin Fissures (a crack in the skin): 6 people, 100.00%
  2. Skin Exfoliation (removal of the oldest dead skin cells): 6 people, 100.00%
  3. Rashes (redness): 6 people, 100.00%
  4. Bleeding Into The Skin: 6 people, 100.00%
  5. Skin Haemorrhage (bleeding into skin): 5 people, 83.33%
  6. Skin Discoloration - Bluish (bluish colour of skin): 5 people, 83.33%
  7. Microangiopathy (disease of the capillaries (very small blood vessels), in which the capillary walls become so thick and weak that they bleed, leak protein): 3 people, 50.00%
  8. Drug Hypersensitivity: 2 people, 33.33%
  9. White Blood Cells Urine Positive: 1 person, 16.67%
  10. International Normalised Ratio Decreased: 1 person, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Raynaud's phenomenon?

Check whether Raynaud's phenomenon is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Treatments, associated drugs and conditions:

COVID vaccines that are related to Raynaud's phenomenon:

Common drugs associated with Raynaud's phenomenon:

All the drugs that are associated with Raynaud's phenomenon:

Common conditions associated with Raynaud's phenomenon:

All the conditions that are associated with Raynaud's phenomenon:

How the study uses the data?

The study is based on Raynaud's phenomenon and Dementia alzheimer's type, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: